These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22310607)

  • 1. Comparison between thymoglobulin and ATGAM as an induction agent in adult kidney transplantation: a single-center experience.
    Kim JM; Jang HR; Ko JS; Kwon CH; Kwak MS; Hur WS; Kim SJ; Kim GS; Joh JW; Lee SK; Oh HY
    Transplant Proc; 2012 Jan; 44(1):171-4. PubMed ID: 22310607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function.
    Chen G; Gu J; Qiu J; Wang C; Fei J; Deng S; Li J; Huang G; Fu Q; Chen L
    Exp Clin Transplant; 2013 Aug; 11(4):310-4. PubMed ID: 23121641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.
    Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY
    Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with thymoglobulin and antithymocyte globulin-Fresenius as induction therapy in renal transplant patients: a retrospective study.
    Cicora F; Mos F; Paz M; Roberti J
    Exp Clin Transplant; 2013 Oct; 11(5):418-22. PubMed ID: 23909577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and safety between rabbit anti-thymocyte globulin and anti-T lymphocyte globulin in kidney transplantation from donation after cardiac death: a retrospective cohort study.
    Chen GD; Lai XQ; Ko DS; Qiu J; Wang CX; Han M; Li J; Huang G; He XS; Chen LZ
    Nephrology (Carlton); 2015 Aug; 20(8):539-43. PubMed ID: 25808082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients.
    Khanmoradi K; Knorr JP; Feyssa EL; Parsikia A; Jawa P; Dinh DB; Campos S; Zaki RF; Ortiz JA
    Exp Clin Transplant; 2013 Jun; 11(3):222-8. PubMed ID: 23432665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction therapy by anti-thymocyte globulin (rabbit) versus basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes.
    Foster CE; Weng RR; Piper M; Laugenou K; Ichii H; Lakey J; Malinoski D
    Transplant Proc; 2012 Jan; 44(1):164-6. PubMed ID: 22310605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
    Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
    Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients.
    Kuo HT; Huang E; Emami S; Pham PT; Wilkinson AH; Danovitch GM; Bunnapradist S
    Transplantation; 2012 Mar; 93(5):493-502. PubMed ID: 22306574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes associated with induction regimens among retransplant kidney recipients in the United States.
    Schold J; Poggio E; Goldfarb D; Kayler L; Flechner S
    Transplantation; 2015 Jun; 99(6):1165-71. PubMed ID: 25606788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients.
    Brennan DC; Flavin K; Lowell JA; Howard TK; Shenoy S; Burgess S; Dolan S; Kano JM; Mahon M; Schnitzler MA; Woodward R; Irish W; Singer GG
    Transplantation; 1999 Apr; 67(7):1011-8. PubMed ID: 10221486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of long-term effect of thymoglobulin treatment in patients with a high risk of delayed graft function.
    Requião-Moura LR; Ferraz E; Matos AC; Tonato EJ; Ozaki KS; Durão MS; Câmara NO; Pacheco-Silva A
    Transplant Proc; 2012 Oct; 44(8):2428-33. PubMed ID: 23026612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results.
    Hardinger KL; Rhee S; Buchanan P; Koch M; Miller B; Enkvetchakul D; Schuessler R; Schnitzler MA; Brennan DC
    Transplantation; 2008 Oct; 86(7):947-52. PubMed ID: 18852661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.
    Gaber AO; First MR; Tesi RJ; Gaston RS; Mendez R; Mulloy LL; Light JA; Gaber LW; Squiers E; Taylor RJ; Neylan JF; Steiner RW; Knechtle S; Norman DJ; Shihab F; Basadonna G; Brennan DC; Hodge EE; Kahan BD; Kahan L; Steinberg S; Woodle ES; Chan L; Ham JM; Schroeder TJ
    Transplantation; 1998 Jul; 66(1):29-37. PubMed ID: 9679818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: a single-center report.
    Khositseth S; Matas A; Cook ME; Gillingham KJ; Chavers BM
    Transplantation; 2005 Apr; 79(8):958-63. PubMed ID: 15849550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S; Alexander JW; Schroeder TJ; First MR
    Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
    Indudhara R; Novick AC; Hodge E; Goormastic M; Papajcik D; Mastroianni B; Cook D
    Urology; 1996 Jun; 47(6):807-12. PubMed ID: 8677568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comparison of Two Types of Rabbit Antithymocyte Globulin Induction Therapy in Immunological High-Risk Kidney Recipients: A Prospective Randomized Control Study.
    Burkhalter F; Schaub S; Bucher C; Gürke L; Bachmann A; Hopfer H; Dickenmann M; Steiger J; Binet I
    PLoS One; 2016; 11(11):e0165233. PubMed ID: 27855166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.
    Whitson BA; Kilic A; Lehman A; Wehr A; Hasan A; Haas G; Hayes D; Sai-Sudhakar CB; Higgins RS
    Clin Transplant; 2015 Jan; 29(1):9-17. PubMed ID: 25284138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.